PL2634191T3 - Sposób wytwarzania pochodnych tienopirymidynodionu - Google Patents

Sposób wytwarzania pochodnych tienopirymidynodionu

Info

Publication number
PL2634191T3
PL2634191T3 PL13002731T PL13002731T PL2634191T3 PL 2634191 T3 PL2634191 T3 PL 2634191T3 PL 13002731 T PL13002731 T PL 13002731T PL 13002731 T PL13002731 T PL 13002731T PL 2634191 T3 PL2634191 T3 PL 2634191T3
Authority
PL
Poland
Prior art keywords
thienopyrimidinedione
preparing derivatives
derivatives
preparing
Prior art date
Application number
PL13002731T
Other languages
English (en)
Inventor
Sukeerthi Kumar
Abraham Thomas
Nayan Taterao Waghmare
Sanjay Margal
Neelima Khairatkar-Joshi
Indranil Mukhopadhyay
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42780205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2634191(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of PL2634191T3 publication Critical patent/PL2634191T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL13002731T 2009-03-23 2010-03-23 Sposób wytwarzania pochodnych tienopirymidynodionu PL2634191T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
IN2213MU2009 2009-09-23
US25199409P 2009-10-15 2009-10-15
IN2906MU2009 2009-12-16
US29447010P 2010-01-12 2010-01-12
EP10751712.0A EP2411396B1 (en) 2009-03-23 2010-03-23 Thienopyrimidinedione derivatives as trpa1 modulators
EP13002731.1A EP2634191B1 (en) 2009-03-23 2010-03-23 Process for preparing derivatives of thienopyrimidinedione

Publications (1)

Publication Number Publication Date
PL2634191T3 true PL2634191T3 (pl) 2015-06-30

Family

ID=42780205

Family Applications (3)

Application Number Title Priority Date Filing Date
PL10716050T PL2411395T3 (pl) 2009-03-23 2010-03-22 Pochodne furopirymidynodionu jako modulatory TRPA1
PL10751712T PL2411396T3 (pl) 2009-03-23 2010-03-23 Pochodne tienopirymidynodionu jako modulatory TRPA1
PL13002731T PL2634191T3 (pl) 2009-03-23 2010-03-23 Sposób wytwarzania pochodnych tienopirymidynodionu

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL10716050T PL2411395T3 (pl) 2009-03-23 2010-03-22 Pochodne furopirymidynodionu jako modulatory TRPA1
PL10751712T PL2411396T3 (pl) 2009-03-23 2010-03-23 Pochodne tienopirymidynodionu jako modulatory TRPA1

Country Status (22)

Country Link
US (4) US20120178766A1 (pl)
EP (3) EP2411395B1 (pl)
JP (2) JP2012521406A (pl)
KR (2) KR20110128898A (pl)
CN (3) CN102361874A (pl)
AP (1) AP2948A (pl)
AU (2) AU2010227225A1 (pl)
BR (2) BRPI1013705A2 (pl)
CA (2) CA2756535A1 (pl)
DK (3) DK2411395T3 (pl)
EA (2) EA201190138A1 (pl)
ES (3) ES2424341T3 (pl)
HU (1) HUE024538T2 (pl)
IL (2) IL215175A (pl)
MX (1) MX2011009822A (pl)
PE (2) PE20120834A1 (pl)
PL (3) PL2411395T3 (pl)
PT (3) PT2411395E (pl)
SG (4) SG184767A1 (pl)
SI (3) SI2411395T1 (pl)
WO (2) WO2010109329A1 (pl)
ZA (2) ZA201107650B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010227225A1 (en) 2009-03-23 2011-09-15 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as TRPA1 modulators
AU2010227245B2 (en) 2009-03-23 2015-09-10 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
AU2011346763B2 (en) 2010-12-20 2016-01-07 Glenmark Pharmaceuticals S.A. 2-amino-4-arylthiazole compounds as TRPA1 antagonists
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
JP2014517031A (ja) 2011-06-13 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニストを使用した呼吸器疾患の治療
US20140107113A1 (en) * 2011-06-22 2014-04-17 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
WO2013014597A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
US20140364445A1 (en) * 2011-12-05 2014-12-11 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
HK1207643A1 (en) * 2012-06-08 2016-02-05 Glenmark Pharmaceuticals S.A. Amides of 2-amino-4-arylthiazole compounds and their salts
AR092749A1 (es) 2012-10-01 2015-04-29 Orion Corp Compuestos farmaceuticos
CN105307642A (zh) 2013-06-20 2016-02-03 格兰马克药品股份有限公司 包含trpa1拮抗剂的纳米颗粒制剂
US9532988B2 (en) 2013-10-15 2017-01-03 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent
JP6573968B2 (ja) * 2014-08-11 2019-09-11 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． ＴＲＰＣ５調節因子としての、精神神経障害の処置のためのチエノおよびフロ［２，３−ｄ］ピリミジン−２，４［１Ｈ，３Ｈ］−ジオン誘導体
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
WO2016023825A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
US10329265B2 (en) 2014-08-22 2019-06-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
US20190175599A1 (en) * 2014-09-16 2019-06-13 Glemark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
JP2019513749A (ja) 2016-04-07 2019-05-30 デューク ユニバーシティ 衛生化及び麻酔用のｔｒｐｖ４及びｔｒｐａ１の小分子二重阻害剤
CN110461838B (zh) * 2017-03-07 2022-05-06 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
MX2023004008A (es) * 2020-10-14 2023-04-26 Boehringer Ingelheim Int Derivados de tetrazol como inhibidores de trpa1.
US11661430B2 (en) * 2020-10-14 2023-05-30 Boehringer Ingelheim International Gmbh Tetrazole derivatives as TRPA1 inhibitors
CN116940575A (zh) * 2021-02-23 2023-10-24 深圳市康哲药业有限公司 噻吩并嘧啶二酮类化合物及其应用
KR20230170932A (ko) 2021-04-14 2023-12-19 베링거 인겔하임 인터내셔날 게엠베하 TRPA1 억제제로서 3H,4H-티에노[2,3-d]피리미딘-4-온 유도체
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
WO2000012514A1 (en) * 1998-08-28 2000-03-09 Astrazeneca Ab Novel compounds
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
EP1558607B1 (en) * 2002-10-30 2010-05-05 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
US7465581B2 (en) 2002-12-18 2008-12-16 The Scripps Research Institute ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
EP1657238A4 (en) 2003-08-22 2008-12-03 Takeda Pharmaceutical CONDENSATE PYRIMIDINE DERIVATIVE AND ITS USE
JP2007522214A (ja) 2004-02-11 2007-08-09 スミスクライン・ビーチャム・コーポレイション Ｐｔｈアゴニスト
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
WO2006083005A1 (ja) * 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
CA2617788A1 (en) * 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
WO2007054480A1 (en) * 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
US20070105920A1 (en) * 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
JP2009514928A (ja) * 2005-11-08 2009-04-09 ナームローゼ・フエンノートチヤツプ・オルガノン Ｔｒｐｖ１関連障害の治療において有用な２−（ベンゾイミダゾル−１−イル）−ｎ−（４−フェニルチアゾル−２−イル）アセトアミド誘導体
CN101384261B (zh) * 2005-12-22 2011-12-07 海德拉生物科学公司 治疗疼痛的组合物
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AR065081A1 (es) * 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
WO2009002933A1 (en) 2007-06-22 2008-12-31 Hydra Biosciences, Inc. Methods and compositions for treating disorders
WO2009002983A1 (en) * 2007-06-25 2008-12-31 Sandisk Corporation Non-volatile storage with individually controllable shield plates between storage elements
WO2010004390A1 (en) 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
ES2424340T3 (es) 2009-03-23 2013-10-01 Glenmark Pharmaceuticals S.A. Derivados de isotiazolo-pirimidindiona como moduladores de TRPA1
AU2010227225A1 (en) 2009-03-23 2011-09-15 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as TRPA1 modulators
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
WO2011045702A1 (en) 2009-10-15 2011-04-21 Pfizer Inc. Pyrrolo[2,3-d] pyrimidine compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5734313B2 (ja) 2010-01-12 2015-06-17 アーべー・シオンス チアゾールおよびオキサゾールキナーゼ阻害剤
KR101265451B1 (ko) 2010-07-13 2013-05-22 노파르티스 아게 옥사진 유도체, 및 신경계 장애의 치료에 있어서의 그의 용도

Also Published As

Publication number Publication date
CN102361877B (zh) 2014-05-07
US8507503B2 (en) 2013-08-13
IL215177A (en) 2014-01-30
BRPI1009381B8 (pt) 2021-05-25
SI2411395T1 (sl) 2013-07-31
EA201190139A1 (ru) 2012-03-30
DK2634191T3 (en) 2015-03-23
BRPI1009381A2 (pt) 2016-06-21
PE20120834A1 (es) 2012-07-25
PL2411396T3 (pl) 2013-10-31
IL215175A0 (en) 2011-12-29
JP2012521407A (ja) 2012-09-13
EA022029B1 (ru) 2015-10-30
CN103755720B (zh) 2016-07-06
PT2634191E (pt) 2015-03-04
DK2411396T3 (da) 2013-08-05
WO2010109329A1 (en) 2010-09-30
HUE024538T2 (hu) 2016-01-28
US20120295924A1 (en) 2012-11-22
ES2424341T3 (es) 2013-10-01
PE20120775A1 (es) 2012-06-27
WO2010109334A2 (en) 2010-09-30
AU2010227225A1 (en) 2011-09-15
US9474758B2 (en) 2016-10-25
KR20120004422A (ko) 2012-01-12
SI2411396T1 (sl) 2013-07-31
IL215175A (en) 2014-01-30
AU2010227230A2 (en) 2011-10-27
US20130289054A1 (en) 2013-10-31
CN102361877A (zh) 2012-02-22
ZA201107649B (en) 2012-07-25
AP2011005889A0 (en) 2011-10-31
CA2756535A1 (en) 2010-09-30
AU2010227225A2 (en) 2011-10-06
EP2411395B1 (en) 2013-05-29
HK1166074A1 (en) 2012-10-19
PT2411395E (pt) 2013-06-06
SG174404A1 (en) 2011-10-28
PT2411396E (pt) 2013-06-06
ZA201107650B (en) 2012-07-25
JP5612070B2 (ja) 2014-10-22
CN103755720A (zh) 2014-04-30
KR101524337B1 (ko) 2015-05-29
AU2010227230A1 (en) 2011-09-22
EP2411396A2 (en) 2012-02-01
HK1166073A1 (en) 2012-10-19
IL215177A0 (en) 2011-12-29
SI2634191T1 (sl) 2015-04-30
CA2756536C (en) 2015-10-06
ES2424342T3 (es) 2013-10-01
EP2634191B1 (en) 2014-12-24
JP2012521406A (ja) 2012-09-13
US8987278B2 (en) 2015-03-24
EP2411396B1 (en) 2013-05-29
AU2010227230B2 (en) 2015-11-26
EP2634191A1 (en) 2013-09-04
MX2011009822A (es) 2012-01-25
ES2532386T3 (es) 2015-03-26
WO2010109334A3 (en) 2010-11-25
SG184767A1 (en) 2012-10-30
SG184769A1 (en) 2012-10-30
SG174398A1 (en) 2011-10-28
CA2756536A1 (en) 2010-09-30
BRPI1009381B1 (pt) 2020-04-14
PL2411395T3 (pl) 2013-10-31
US20120178766A1 (en) 2012-07-12
BRPI1013705A2 (pt) 2016-04-05
EP2411395A1 (en) 2012-02-01
AP2948A (en) 2014-07-31
DK2411395T3 (da) 2013-08-05
EA201190138A1 (ru) 2013-05-30
US20150150876A1 (en) 2015-06-04
CN102361874A (zh) 2012-02-22
KR20110128898A (ko) 2011-11-30

Similar Documents

Publication Publication Date Title
PT2634191E (pt) Processo para preparar derivados de tienopirimidinadiona
PL2614826T3 (pl) Sposób wytwarzania pochodnych tiazolu
IL218101A0 (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
PT3260457T (pt) Processo para preparar derivados e intermediários de carbamoilpiridona
IL214600A0 (en) Process for preparing substituted 2-nitrobiphenyls
ZA201202504B (en) Process for the preparation of calcobutrol
IL220357A0 (en) Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranoses
IL222290A0 (en) Process for preparing aminobenzofuran derivatives
IL222191A0 (en) Process for preparing sulfonamido-benzofuran derivatives
IL220211A0 (en) Process for the preparation of 1-alkyl-/1-aryl-5-pyrazolecarboxylic acid derivatives
PL390042A1 (pl) Sposób wytwarzania kwasu chlebowego
IL218140A0 (en) Process for preparing 1-phenylpyrazoles
PL388931A1 (pl) Sposób otrzymywania fluorokarbofunkcyjnych silseskwioksanów
ZA201107695B (en) Process for production pyripyropene derivatives
IL227220A (en) A process for preparing a history of 3-alkylsulfinylbenzoyl
SI2477964T1 (sl) Postopek za pripravo derivatov alfa-karboksamida
EP2456778A4 (en) PROCESS FOR PRODUCING FLUOROCYTIDINE DERIVATIVES
IL219138A0 (en) Process for the preparation of 4-sulfinyl-pyrazole derivatives
IL214764A0 (en) Process for the preparation of pyrazole derivatives
EP2619174A4 (en) PROCESS FOR THE PREPARATION OF L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES
HUP0900788A2 (en) Process for producing 4-bromomethyl-biphenyl derivatives
EP2423187A4 (en) PROCESS FOR PRODUCING N-ALCOXYCARBONYL-tert-LEUCINS
IL226097A0 (en) A process for the production of derivatives of 4-carbonyloxyquinoline
IL217460A0 (en) Novel process for the preparation of 4-aminobut-2-enolides
IL220160A (en) A process for the preparation of defrasirox